STOCK TITAN

EvokAI Creative - OKAIF STOCK NEWS

Welcome to our dedicated page for EvokAI Creative news (Ticker: OKAIF), a resource for investors and traders seeking the latest updates and insights on EvokAI Creative stock.

EvokAI Creative Labs Inc. (OKAIF) delivers AI-powered healthcare solutions through advanced machine learning and data analytics. This dedicated news hub provides investors and medical professionals with essential updates on the company's technological advancements and industry impact.

Access official press releases covering clinical validation milestones, research partnerships, and regulatory developments. Our curated collection includes earnings reports, product launch details, and strategic initiatives that demonstrate OKAIF's role in transforming medical diagnostics and treatment optimization.

Stay informed about key developments in AI-driven healthcare innovation through verified updates on therapeutic applications, data security protocols, and cross-industry collaborations. This resource enables stakeholders to track technological progress while understanding its implications for modern healthcare systems.

Bookmark this page for continuous access to EvokAI Creative's latest announcements and analysis of its growing influence in MedTech. Regularly updated content ensures you maintain awareness of critical developments shaping AI applications in clinical environments.

Rhea-AI Summary

EvokAI Creative Labs has announced the completion of its previously disclosed 10:1 share consolidation, effective February 05, 2025. Following the consolidation, the company will have approximately 7,605,493 common shares outstanding.

The consolidation will be implemented under new CUSIP (30053J200) and ISIN (CA30053J2002) numbers. Shareholders holding uncertificated shares will have their accounts automatically adjusted by Endeavor Trust or their respective brokers. Registered shareholders with physical certificates will receive instructions for surrendering their current certificates for post-consolidation replacements.

The company expects this consolidation to potentially increase financial community interest, broaden its investor base, improve trading liquidity, and reduce shareholder transaction costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
EvokAI Creative Labs Inc. has announced that its 'MDM Flex Sensor' has received the CE Mark approval, a significant milestone for the healthcare sector. The integration of this micro sensor into the EvokAI Movement Disorder Monitor is expected to revolutionize patient care and improve their quality of life. The company aims to expand its market reach in Europe and the US market, with the potential to reduce the economic burden of movement disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
EvokAI Creative Labs Inc. has commenced the CE Mark certification process for its 'MDM Flex Sensor' technology for Parkinson's disease management. The technology aims to improve patient outcomes, provide personalized care, enable remote monitoring, and has undergone rigorous clinical validation. Upon certification, it will be available to patients in Europe, addressing unmet medical needs globally. The completion of testing and certification is expected by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
EvokAI Creative

OTC:OKAIF

OKAIF Rankings

OKAIF Stock Data

908.48k
7.61M
53.3%
Health Information Services
Healthcare
Link
Canada
Vancouver